Report Sees Slowing Growth in PET Scans

“This represents a continued slowing in the annual growth rate for PET patient studies."

The current numbers compare to annual growth from 2008 to 2010 of about 7%, and to annual growth between 2005 and 2008 of 10%. Ms. Young noted that in 2011, most of the growth was from an increase in the number of sites providing PET services; the average procedure increase per site was only 0.6% when compared to 2010. These PET studies were performed in 2,210 hospital and nonhospital sites, using fixed or mobile PET/CT or PET scanners.

Oncology continues to drive the use of PET imaging procedures, as hospitals open cancer treatment centers and install PET/CT scanners to support their oncology services. The study found that about 94% of all PET studies in 2012 were for cancer, distributed between diagnosis (19%), staging (38%), treatment planning (13%), and follow up (30%). Neurology and cardiology applications make up the remaining 6% of procedures, divided evenly between the two.

Used for 96% of all PET procedures in 2011, fluorine-18 fluorodeoxyglucose (FDG) is still the mainstay of PET imaging. Rubidium-82, the next most frequently used radiopharmaceutical, was used for about 2% of all procedures, as problems with the supply of the radiopharmaceutical continued to limit its use for cardiac perfusion studies.

IMV is a leader in market research and online publishing for the medical imaging and clinical diagnostic instruments markets.

Related Links:
IMV